LUCD RSI Chart
Last 7 days
8.0%
Last 30 days
5.6%
Last 90 days
-25.2%
Trailing 12 Months
-36.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 634.0K | 793.0K | 1.5M | 2.4M |
2022 | 533.0K | 481.0K | 429.0K | 377.0K |
2021 | 0 | 0 | 0 | 585.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 15, 2024 | pavmed inc. | sold | - | - | -3,331,750 | - |
Jan 26, 2024 | pavmed inc. | acquired | 4,675,470 | 1.4033 | 3,331,770 | - |
Sep 26, 2023 | lapidus stanley | sold | -43,173 | 1.45134 | -29,747 | - |
Sep 25, 2023 | lapidus stanley | sold | -286 | 1.43 | -200 | - |
Sep 21, 2023 | lapidus stanley | sold | -144 | 1.44 | -100 | - |
Sep 20, 2023 | lapidus stanley | sold | -5,530 | 1.44892 | -3,817 | - |
Nov 30, 2022 | pavmed inc. | acquired | 6,474,470 | 1.91823 | 3,375,240 | - |
Nov 30, 2022 | pavmed inc. | acquired | 6,474,460 | 1.91823 | 3,375,230 | - |
Which funds bought or sold LUCD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -1,079 | - | -% |
May 03, 2024 | Geneos Wealth Management Inc. | unchanged | - | -20,310 | 27,419 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 25, 2024 | Allworth Financial LP | new | - | 128 | 128 | -% |
Apr 24, 2024 | Newbridge Financial Services Group, Inc. | new | - | 40.00 | 40.00 | -% |
Apr 22, 2024 | Byrne Asset Management LLC | sold off | -100 | -9,518 | - | -% |
Apr 15, 2024 | THOMPSON INVESTMENT MANAGEMENT, INC. | new | - | 1.00 | 1.00 | -% |
Apr 05, 2024 | CWM, LLC | new | - | 1,000 | 1,000 | -% |
Apr 02, 2024 | M&R CAPITAL MANAGEMENT INC | new | - | 20.00 | 20.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.1 | 87,759 | 468,671 | -% |
Unveiling Lucid Diagnostics Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Lucid Diagnostics Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 182.6B | 40.3B | 32.45 | 4.53 | ||||
BDX | 67.4B | 19.7B | 50.6 | 3.42 | ||||
ALGN | 20.6B | 3.9B | 44.54 | 5.26 | ||||
BAX | 18.2B | 14.9B | 6.88 | 1.22 | ||||
MID-CAP | ||||||||
ATR | 10.0B | 3.5B | 31.94 | 2.82 | ||||
HSIC | 9.3B | 12.5B | 24.01 | 0.75 | ||||
BIO | 7.8B | 2.7B | -12.29 | 2.93 | ||||
XRAY | 5.8B | 3.9B | -61.76 | 1.47 | ||||
AXNX | 3.4B | 387.1M | -215.56 | 8.87 | ||||
PDCO | 2.3B | 6.6B | 11.98 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.85 | 0.4 | ||||
ANIK | 423.5M | 166.7M | -5.12 | 2.54 | ||||
ANGO | 236.7M | 324.0M | -1.23 | 0.73 | ||||
APYX | 45.4M | 52.3M | -2.43 | 0.87 | ||||
AEMD | 3.3M | 3.7M | -0.27 | 0.88 |
Lucid Diagnostics Inc. News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | 32.8% | 1,040,000 | 783,000 | 159,000 | 446,000 | 112,000 | 76,000 | - | 189,000 | 166,500 | 144,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | 369,000 | - | 144,273 |
Gross Profit | - | - | - | - | - | 112,000 | 76,000 | - | -180,000 | - | 200,000 |
Operating Expenses | 4.9% | 12,493,000 | 11,911,000 | 11,743,000 | 14,763,000 | 15,087,000 | 14,453,000 | 14,628,000 | 12,460,000 | 11,540,500 | 6,710,000 |
S&GA Expenses | 14.9% | 4,408,000 | 3,837,000 | 4,032,000 | 4,127,000 | 5,013,000 | 3,930,000 | 3,873,000 | 3,318,000 | 2,632,500 | 918,000 |
R&D Expenses | 6.7% | 1,723,000 | 1,615,000 | 1,827,000 | 2,282,000 | 2,337,000 | 2,704,000 | 3,440,000 | 2,881,000 | 3,481,500 | 2,190,000 |
EBITDA Margin | -Infinity% | -20.49 | - | -13.51 | -14.88 | -15.00 | -17.70 | -20.85 | -26.83 | -46.86 | - |
Interest Expenses | -92.6% | 11,000 | 149,000 | 223,000 | 33,000 | - | - | - | - | - | 447,000 |
Earnings Before Taxes | 23.8% | -10,830,000 | -14,208,000 | -11,381,000 | -16,247,000 | -14,928,000 | -14,349,000 | -14,624,000 | -12,270,000 | -11,305,500 | -6,957,000 |
EBT Margin | -81.0% | -21.69 | -11.98 | -14.12 | -15.54 | -15.54 | -18.39 | -21.51 | -27.34 | -48.00 | - |
Net Income | 23.8% | -10,830,000 | -14,208,000 | -11,381,000 | -16,247,000 | -14,928,000 | -14,349,000 | -14,624,000 | -12,270,000 | -11,305,500 | -6,957,000 |
Net Income Margin | -81.0% | -21.69 | -11.98 | -14.12 | -15.54 | -15.54 | -18.39 | -21.51 | -27.34 | -48.00 | - |
Free Cashflow | -13.4% | -9,979,000 | -8,798,000 | -7,029,000 | -7,062,000 | -4,258,000 | -7,346,000 | -15,357,000 | -5,924,000 | -10,701,000 | -2,210,000 |
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
Assets | -18.0% | 27.00 | 33.00 | 42.00 | 49.00 | 33.00 | 38.00 | 45.00 | 62.00 | 59.00 | 3.00 | 2.00 |
Current Assets | -19.2% | 22.00 | 27.00 | 36.00 | 42.00 | 24.00 | 30.00 | 36.00 | 52.00 | 57.00 | 3.00 | 1.00 |
Cash Equivalents | -21.4% | 19.00 | 24.00 | 33.00 | 40.00 | 22.00 | 27.00 | 33.00 | 48.00 | 54.00 | 0.00 | 0.00 |
Inventory | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | - |
Net PPE | 3.9% | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - |
Liabilities | -3.6% | 30.00 | 31.00 | 27.00 | 24.00 | 9.00 | 11.00 | 9.00 | 16.00 | 4.00 | 27.00 | 16.00 |
Current Liabilities | -2.8% | 29.00 | 30.00 | 27.00 | 23.00 | 8.00 | 10.00 | 8.00 | 14.00 | 4.00 | - | - |
Shareholder's Equity | -190.4% | -2.31 | 3.00 | 15.00 | 25.00 | 23.00 | 28.00 | 36.00 | 46.00 | 55.00 | - | - |
Retained Earnings | -7.7% | -150 | -139 | -125 | -114 | -98.07 | -83.15 | -68.80 | -54.17 | -41.90 | -30.60 | -13.83 |
Additional Paid-In Capital | 0.7% | 130 | 129 | 127 | 126 | 121 | 111 | 105 | 101 | 97.00 | 6.00 | 0.00 |
Shares Outstanding | 0% | 42.00 | 42.00 | 42.00 | 42.00 | 41.00 | 36.00 | 35.00 | 35.00 | 35.00 | 14.00 | 14.00 |
Float | - | - | - | 14.00 | - | - | - | 19.00 | - | - | 81.00 | - |
Cashflow (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Cashflow From Operations | -13.4% | -9,962 | -8,781 | -7,012 | -7,045 | -4,258 | -6,346 | -13,305 | -5,776 | -9,877 | -2,182 | -2,294 | -3,315 | - | - |
Share Based Compensation | -27.5% | 748 | 1,032 | 1,165 | 2,817 | 3,488 | 3,280 | 3,554 | 3,537 | - | - | - | - | - | - |
Cashflow From Investing | -1150.0% | -175 | -14.00 | -15.00 | -17.00 | -203 | -1,321 | -2,436 | -148 | -824 | -28.00 | -1.00 | -9.00 | - | - |
Cashflow From Financing | 1718.2% | 5,000 | 275 | 75.00 | 24,110 | 1.00 | 1,922 | 501 | 187 | 64,336 | - | 4,439 | 3,300 | - | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |||
Income Statement [Abstract] | ||||
Revenue | $ 2,428 | $ 377 | ||
Operating expenses: | ||||
Cost of revenue | 5,979 | 3,614 | ||
Sales and marketing | 16,404 | 16,134 | ||
General and administrative | 19,254 | 23,974 | ||
Amortization of acquired intangible assets | 2,021 | 1,649 | ||
Research and development | 7,252 | 11,257 | ||
Total operating expenses | 50,910 | 56,628 | ||
Operating loss | (48,482) | (56,251) | ||
Other income (expense): | ||||
Interest income | 424 | 88 | ||
Interest expense | (416) | (8) | ||
Change in fair value - Senior Secured Convertible Note | (2,980) | |||
Loss on issue and offering costs - Senior Secured Convertible Note | (1,186) | |||
Debt extinguishments loss - Senior Secured Convertible Note | (26) | |||
Other income (expense), net | (4,184) | 80 | ||
Loss before provision for income tax | (52,666) | (56,171) | ||
Provision for income taxes | ||||
Net loss | $ (52,666) | $ (56,171) | ||
Net loss per share - basic | [1] | $ (1.26) | $ (1.55) | |
Net loss per share - diluted | [1] | $ (1.26) | $ (1.55) | |
Weighted average common shares outstanding, basic | 41,756,129 | 36,172,421 | ||
Weighted average common shares outstanding, diluted | 41,756,129 | 36,172,421 | ||
|
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash | $ 18,896 | $ 22,474 |
Accounts receivable | 45 | 17 |
Inventory | 278 | 111 |
Prepaid expenses, deposits, and other current assets | 2,854 | 1,754 |
Total current assets | 22,073 | 24,356 |
Fixed assets, net | 1,334 | 1,592 |
Operating lease right-of-use assets | 1,307 | 2,008 |
Intangible assets, net | 1,424 | 3,445 |
Other assets | 1,132 | 1,108 |
Total assets | 27,270 | 32,509 |
Current liabilities: | ||
Accounts payable | 1,146 | 1,056 |
Accrued expenses and other current liabilities | 3,841 | 1,447 |
Operating lease liabilities, current portion | 1,106 | 962 |
Senior Secured Convertible Note - at fair value | 13,950 | |
Due To: PAVmed Inc. - MSA Fee and operating expenses | 9,339 | 4,960 |
Total current liabilities | 29,382 | 8,425 |
Operating lease liabilities, less current portion | 199 | 1,037 |
Total liabilities | 29,581 | 9,462 |
Commitments and contingencies | ||
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series A and Series A-1 Convertible Preferred Stock, issued and outstanding 18,625 at December 31, 2023 and no shares issued and outstanding at December 31, 2022 | 18,625 | |
Common stock, $0.001 par value, 200,000,000 shares authorized; 42,329,864 and 40,518,792 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 42 | 41 |
Additional paid-in capital | 129,763 | 121,081 |
Accumulated deficit | (150,741) | (98,075) |
Total Stockholders’ Equity (Deficit) | (2,311) | 23,047 |
Total Liabilities and Stockholders’ Equity (Deficit) | $ 27,270 | $ 32,509 |